Healthcare Industry News: dihydroergotamine
News Release - July 26, 2007
MAP Pharmaceuticals Appoints General CounselMOUNTAIN VIEW, Calif., July 26 (HSMN NewsFeed) -- MAP Pharmaceuticals, Inc. today announced the appointment of Charlene A. Friedman as Vice President, General Counsel and Secretary.
"We are very pleased to add such a talented and experienced executive to our senior management team," said Mr. Nelson. "Charlene's in-depth knowledge of the healthcare industry and broad legal, commercial and regulatory experience with public life science companies will be important as our company continues to grow."
Ms. Friedman has been practicing law for more than 25 years, including serving as General Counsel at several public biopharmaceutical and medical device companies for more than 10 years. Prior to joining MAP Pharmaceuticals, Ms. Friedman served as Vice President, General Counsel and Secretary of VNUS Medical Technologies, Inc., where she provided legal counsel on general corporate matters, financial and other SEC filings, direct-to-consumer advertising and other sales and marketing materials, Sarbanes-Oxley matters and business development transactions.
Previously, Ms. Friedman served as Vice President, General Counsel and Secretary for Aviron, a publicly-traded biopharmaceutical company and R2 Technology, Inc., a privately-held medical device company. She also held the position of Vice President, Legal and Regulatory Affairs, General Counsel and Assistant Secretary at Collagen Aesthetics, Inc., a publicly-traded medical device company. Ms. Friedman is a member of the California and Massachusetts state bars and holds a B.A. from Tufts University and a J.D. from the Northeastern University School of Law.
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
Source: MAP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.